Key takeaways
- Low-dose naltrexone (LDN) uses a small fraction of the standard naltrexone dose, where the drug appears to act through a different mechanism than it does at full strength.
- At low doses, researchers propose it works on glial cells and immune signaling through the toll-like receptor 4 (TLR4) pathway, dampening neuroinflammation rather than acting purely as an opioid blocker.
- A 2020 controlled human trial mapped its dose-response in fibromyalgia, and a 2020 systematic review pooled the evidence across several chronic-pain conditions.
- Two completed randomized, placebo-controlled fibromyalgia trials (the phase 2 FINAL study and a phase 4 crossover study) have studied LDN against placebo for pain, deepening the human evidence base.
- The body of large, long-term human trials is still maturing. As a prescription medication, LDN is used under licensed physician oversight, with attention to its interaction with opioid medications.
What Is Low-Dose Naltrexone?
Naltrexone is a long-established medication, used at higher doses to help manage opioid and alcohol dependence by blocking opioid receptors. Low-dose naltrexone, or LDN, refers to using a small fraction of that standard dose, typically in the range of 1 to 5 mg per day. At these lower amounts, the drug appears to behave quite differently from how it works at full strength.
That difference is the whole reason LDN is studied as its own approach. A 2018 review in Medical Sciences summarizes the pharmacology: at standard doses naltrexone is a straightforward opioid antagonist, while at low doses it engages additional pathways that are not active at the higher dose.
How It Is Thought to Work
At standard doses, naltrexone occupies opioid receptors continuously. The mechanism proposed for low-dose use is different. The 2018 Medical Sciences review describes how, at low doses, naltrexone influences glial cells in the nervous system and modulates immune signaling, specifically through a pathway involving toll-like receptor 4 (TLR4). Glial cells help regulate inflammation in the brain and spinal cord, and overactive glial signaling has been linked to persistent pain states. By quieting that signaling, a low dose is thought to reduce the neuroinflammation that sustains chronic pain.
This mechanism comes largely from laboratory and preclinical work, so it is best understood as the leading explanation rather than a fully settled one. It gives a plausible reason why a small dose might calm overactive glial signaling, and it is the model that shapes how researchers design the human trials.
The Human Evidence
Most of the human research on LDN centers on fibromyalgia. A 2020 trial published in Pain Medicine mapped the dose-response relationship of low-dose naltrexone in women with fibromyalgia, estimating that a dose around 4.5 mg was a relevant test dose and noting that the symptoms that responded varied considerably from person to person. The authors recommended that future placebo-controlled randomized trials build on those findings.
Those larger trials followed. The FINAL study (NCT04270877) was a phase 2 randomized, double-blind, placebo-controlled trial that enrolled 99 women with fibromyalgia and compared LDN against placebo for pain over 12 weeks; it completed in late 2022. A separate randomized, double-blind, placebo-controlled crossover study run at Rigshospitalet in Denmark (NCT02806440) enrolled 58 fibromyalgia patients and was designed to test whether LDN relieves pain through a central nervous system mechanism, in line with the proposed glial pathway. Both registries describe the design, blinding, and outcome measures that make these meaningful tiers of evidence.
A 2020 systematic review in Current Pain and Headache Reports pooled the available research on LDN across a range of chronic-pain conditions, including fibromyalgia, inflammatory bowel conditions, and multiple sclerosis, weighing multiple studies together rather than relying on any single result. The controlled fibromyalgia trials are the most rigorous data in that pool, and the field is still building the large, long-term evidence that characterizes who benefits most and over what timeframe.
What It Is Being Explored For
The strongest human data sit with chronic pain and fibromyalgia. The same glial and immune mechanism is why LDN draws interest for other conditions thought to involve neuroinflammation or immune dysregulation, such as inflammatory bowel conditions and multiple sclerosis, both of which the systematic review touches on. The evidence in those settings is thinner than the fibromyalgia trials and remains earlier-stage.
Whether LDN suits a given person is a question for a licensed physician after reviewing that person's full history. It can interact with opioid medications, and the dose, timing, and monitoring are decisions a prescribing clinician makes.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Low-Dose Naltrexone (LDN) is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.